Tscan Therapeutics Inc (TCRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2021 | 12-2020 | 09-2020 | 06-2020 | 03-2020 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -7,912 | -26,127 | -18,320 | -11,150 | -5,537 |
| Depreciation Amortization | 469 | 1,230 | 834 | 488 | 222 |
| Accounts payable and accrued liabilities | 162 | 1,127 | 1,071 | 505 | 469 |
| Other Working Capital | -2,858 | 21,357 | 21,448 | 20,542 | 75 |
| Other Operating Activity | 182 | -610 | -706 | -269 | -358 |
| Operating Cash Flow | $-9,957 | $-3,023 | $4,327 | $10,116 | $-5,129 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -2,959 | -4,238 | -2,853 | -1,510 | -1,187 |
| Investing Cash Flow | $-2,959 | $-4,238 | $-2,853 | $-1,510 | $-1,187 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 108 | 288 | 248 | 247 | 221 |
| Other Financing Activity | 99,518 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | $99,626 | $288 | $248 | $247 | $221 |
| Beginning Cash Position | 35,386 | 42,359 | 42,359 | 42,359 | 42,359 |
| End Cash Position | 122,096 | 35,386 | 44,081 | 51,212 | 36,264 |
| Net Cash Flow | $86,710 | $-6,973 | $1,722 | $8,853 | $-6,095 |
| Free Cash Flow | |||||
| Operating Cash Flow | -9,957 | -3,023 | 4,327 | 10,116 | -5,129 |
| Capital Expenditure | -2,959 | -4,238 | -2,853 | -1,510 | -1,187 |
| Free Cash Flow | -12,916 | -7,261 | 1,474 | 8,606 | -6,316 |